Bilateral Auricular Vagus Nerve Stimulation for Misophonia

A 64-year-old patient with severe misophonia saw her primary symptom score drop from 80 to 9 after a one-month trial of a non-invasive nerve stimulation device, with effects holding a month later. The case study, led by researchers Francesca Proietti, Massimo Marano, and Emanuele Rizzo, provides the first documented evidence that bilateral transcutaneous auricular vagus nerve stimulation (taVNS) could be a viable intervention for misophonia marked by strong physical reactions.

A Sound Triggering Terror: The Patient’s Profile

The patient’s misophonia was profound and specific. Her main trigger was the rhythmic thudding sound of a nearby basketball being bounced. Exposure didn’t cause mere irritation; it provoked an intense autonomic storm. She experienced acute anxiety, terror, palpitations, a choking sensation, shortness of breath (dyspnea), and an overwhelming urge to flee. These reactions led to significant avoidance behaviors and impaired her daily functioning. She was already on a stable dose of sertraline, an SSRI antidepressant, indicating her condition was severe enough to warrant prior pharmaceutical intervention, yet her symptoms persisted.

Methodology: Stimulating the Calming Nerve via the Ear

The research team proposed a novel approach focusing on the body’s stress response system. Misophonic reactions often involve autonomic dysregulation—a hyperactive “fight-or-flight” response mediated by the sympathetic nervous system. The vagus nerve is a primary component of the parasympathetic nervous system, which counteracts this stress response and promotes calm.

The intervention was bilateral transcutaneous auricular vagus nerve stimulation (taVNS). This non-invasive method uses a small device with ear electrodes to deliver a mild electrical current to branches of the vagus nerve in the outer ear. The patient self-administered the stimulation at home for 60 minutes daily over one month. The intensity was set to a level she could feel but that was not painful.

Assessments were conducted at three points: before treatment, immediately after the one-month protocol, and at a one-month follow-up. The team used the Duke Misophonia Questionnaire Symptoms Composite Scale as the primary measure, alongside standardized tools for psychological distress, anxiety, depression, sleep quality, and functional impairment. For more on the physiological targets of such neuromodulation, see our related article on Cervical Stimulation for Tinnitus and Hearing Disorders.

Findings: A Dramatic Drop in Symptom Severity

The results were striking. The patient’s score on the Duke Misophonia Questionnaire plummeted from a baseline of 80 (indicating severe symptoms) to 9 post-treatment. At the one-month follow-up, it was essentially unchanged at 5, demonstrating a sustained reduction in the core misophonic reaction.

Secondary measures also showed improvement. Scores for overall psychological distress, somatization (physical symptoms from distress), anxiety, hostility, and depressive symptoms all decreased. Sleep quality improved immediately after treatment, though it returned to baseline levels by follow-up.

One finding, however, was complex. While the patient’s direct reaction to trigger sounds lessened dramatically, her self-reported functional impairment followed a different path. It decreased right after treatment but increased slightly at the one-month follow-up. The authors suggest this indicates a “dissociation between symptom reduction and perceived functional recovery.” In simpler terms, the brain’s alarm reaction to the sound quieted, but the long-term habits of avoidance and the psychological impact of years of distress may take longer to resolve. This highlights a critical point for therapy, aligning with concepts explored in Misophonia: Emotional Regulation and Uncertainty Intolerance.

Practical Implications and Future Research

This case study, detailed in the source paper available via DOI: 10.3389/fpsyg.2026.1903444, is explicitly preliminary. It is a single case report, not a controlled trial. The patient remained on sertraline, so the effect of taVNS as an adjunctive therapy cannot be fully isolated.

Yet, its implications are meaningful. It provides a proof of concept that directly targeting autonomic hyperarousal through the vagus nerve may be a viable path for a subset of patients with misophonia. The approach is non-invasive, can be performed at home, and in this case, had no reported adverse effects.

The research strongly argues for the next step: controlled clinical trials. These would compare taVNS to a sham (placebo) device in a larger group of patients, potentially both on and off other medications, to establish true efficacy and optimal treatment protocols. The findings also reinforce the model of misophonia as a condition with strong physiological roots, connecting it to other stress-response disorders. Readers interested in this connection may find our article on PTSD and Tinnitus: Shared Symptoms and Biology relevant.

For individuals suffering from misophonia, this study represents a new avenue of scientific inquiry. It moves beyond traditional sound therapy and counseling to consider direct neuromodulation of the nervous system’s alarm center. While it is not yet a ready treatment, it signals a tangible direction for future evidence-based interventions.